On Nov. 1, 2021, Novavax announced the completion of its rolling submission to Health Canada for authorization of its COVID-19 vaccine candidate, the first filing of a protein-based COVID-19 vaccine in Canada. In addition, the company completed the submission of all data and modules to the European Medicines Agency (EMA) to support the final regulatory review of its dossier.